Drug intelligence / Profile preview

RS-002

Development stage: Preclinical
Lead developer: Anavex Life Sciences
Administration: Oral

Overview

RS-002 is a preclinical-stage oncology drug candidate being developed by Related Sciences. The program is currently in the late discovery/preclinical phase of development. Detailed information regarding its specific molecular target, mechanism of action, and therapeutic modality has not been publicly disclosed.

Targets

M1 (Muscarinic acetylcholine receptor M1)SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on RS-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-002.

Explore the full profile